Published in Clin Transplant on January 25, 2008
Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Transplantation (2012) 1.58
Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2012) 1.35
AKI associated with cardiac surgery. Clin J Am Soc Nephrol (2014) 1.08
2202 kidney transplant recipients with 10 years of graft function: what happens next? Am J Transplant (2008) 1.02
ABO incompatible renal transplants: Good or bad? World J Transplant (2014) 0.97
Osteomalacia revisited : a report on 28 cases. Clin Rheumatol (2010) 0.94
Long-term outcomes of children after solid organ transplantation. Clinics (Sao Paulo) (2014) 0.94
Immunosuppression in lung transplantation. J Thorac Dis (2014) 0.92
Nox2 is a mediator of chronic CsA nephrotoxicity. Am J Transplant (2012) 0.90
Do cannabinoids have a therapeutic role in transplantation? Trends Pharmacol Sci (2010) 0.87
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction. Arterioscler Thromb Vasc Biol (2013) 0.86
Surgical biology for the clinician: vascular effects of immunosuppression. Can J Surg (2010) 0.84
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83
Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation (2014) 0.82
Calcineurin inhibitors in HLA-identical living related donor kidney transplantation. Nephrol Dial Transplant (2014) 0.81
Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction. Dig Dis Sci (2010) 0.79
Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy. Exp Ther Med (2016) 0.78
Targeted Delivery of Immunomodulators to Lymph Nodes. Cell Rep (2016) 0.77
Microproteinuria for detecting calcineurin inhibitor-related nephrotoxicity after liver transplantation. World J Gastroenterol (2009) 0.76
Current progress in ABO-incompatible kidney transplantation. Kidney Res Clin Pract (2015) 0.76
Psychiatric issues in pediatric organ transplantation. Child Adolesc Psychiatr Clin N Am (2010) 0.76
The feasibility and applications of non-invasive cardiac output monitoring, thromboelastography and transit-time flow measurement in living-related renal transplantation surgery: results of a prospective pilot observational study. Transplant Res (2014) 0.75
Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation. J Ophthalmic Vis Res (2017) 0.75
Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. World J Transplant (2015) 0.75
Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol (2014) 0.75
The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial. J Transplant (2017) 0.75
Interaction between castanospermine an immunosuppressant and cyclosporin A in rat cardiac transplantation. World J Transplant (2016) 0.75
Reviewing 15 years of experience with sirolimus. Transplant Res (2015) 0.75
Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant (2014) 0.75
Nox2 and Cyclosporine-Induced Renal Hypoxia. Transplantation (2016) 0.75
Evidence for the immunosuppressive potential of calcineurin inhibitor-sparing regimens in liver transplant recipients with impaired renal function. J Transplant (2011) 0.75
Conversion to sirolimus of patients with chronic allograft nephropathy--a retrospective analysis of outcome and influencing factors. Langenbecks Arch Surg (2008) 0.75
Management of High-risk Corneal Transplantation. Surv Ophthalmol (2016) 0.75
The Relationship between Mortality of Lung Transplant Recipients and Serum Cyclosporine Levels: Joint Modeling of Time-to-Event Data and Longitudinal Data. Int J Organ Transplant Med (2017) 0.75
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant (2006) 2.86
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl (2005) 2.35
Rabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. Arch Neurol (2005) 2.29
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant (2006) 1.84
Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant (2003) 1.54
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53
Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy. JACC Cardiovasc Interv (2008) 1.53
Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation (2004) 1.51
Liver transplant-associated graft-versus-host disease. Transplantation (2003) 1.43
Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation (2004) 1.21
The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant (2011) 1.20
Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol (2004) 1.09
Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation (2004) 1.06
Patterns and predictors of quality of life at 5 to 10 years after heart transplantation. J Heart Lung Transplant (2007) 1.05
Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant (2011) 1.03
A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant (2005) 1.02
Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients. J Heart Lung Transplant (2007) 1.00
Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant (2005) 0.97
Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant (2004) 0.96
Hope, mood states and quality of life in female heart transplant recipients. J Heart Lung Transplant (2003) 0.96
Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis (2004) 0.95
Hepatitis C-positive donors in heart transplantation. Am J Transplant (2002) 0.94
Graft vs host disease following kidney transplantation using an '0 HLA antigen mismatched' donor. Nephrol Dial Transplant (2006) 0.92
Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation (2003) 0.92
Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardiol (2004) 0.92
Physical activity patterns in heart transplant women. J Cardiovasc Nurs (2005) 0.92
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol (2013) 0.90
Functional status and perceived control influence quality of life in female heart transplant recipients. J Heart Lung Transplant (2004) 0.90
Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant (2011) 0.90
Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol (2004) 0.88
Patterns and predictors of physical functional disability at 5 to 10 years after heart transplantation. J Heart Lung Transplant (2007) 0.87
Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant (2003) 0.87
Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation (2014) 0.87
Regional sharing for adult status 1 candidates: reduction in waitlist mortality. Liver Transpl (2006) 0.86
Physical and psychological attributes of fatigue in female heart transplant recipients. J Heart Lung Transplant (2004) 0.86
Predictors of quality of life at 5 to 6 years after heart transplantation. J Heart Lung Transplant (2005) 0.86
Predictors of physical functional disability at 5 to 6 years after heart transplantation. J Heart Lung Transplant (2005) 0.85
Failing the failing heart: a review of palliative care in heart failure. Rev Cardiovasc Med (2013) 0.84
Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation (2007) 0.84
Arrhythmias after heart transplantation: mechanisms and management. J Am Heart Assoc (2012) 0.83
The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation. Curr Opin Organ Transplant (2012) 0.83
Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study. Eur J Cardiothorac Surg (2005) 0.82
Cause of atrioventricular block in patients after heart transplantation. Transplantation (2003) 0.82
West Nile virus infection in kidney and pancreas transplant recipients in the Dallas-Fort Worth Metroplex during the 2012 Texas epidemic. Transplantation (2014) 0.82
Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. Am J Transplant (2002) 0.81
Symptom frequency and distress from 5 to 10 years after heart transplantation. J Heart Lung Transplant (2009) 0.81
Zero risk tolerance costs lives: loss of transplantable organs due to human immunodeficiency virus nucleic acid testing of potential donors. Prog Transplant (2011) 0.81
Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl (2013) 0.81
Factors associated with stress and coping at 5 and 10 years after heart transplantation. J Heart Lung Transplant (2013) 0.80
Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. Am J Transplant (2002) 0.80
No evidence of PERV infection in healthcare workers exposed to transgenic porcine liver extracorporeal support. Xenotransplantation (2007) 0.79
Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation (2011) 0.79
Results after transplantation using donor hearts with preexisting coronary artery disease. J Thorac Cardiovasc Surg (2003) 0.79
Long-term outcomes of heart transplantation in older recipients. J Heart Lung Transplant (2008) 0.78
Successful use of a pneumatic biventricular assist device as a bridge to transplantation in cardiogenic shock. J Heart Lung Transplant (2011) 0.78
Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience. Clin Transplant (2011) 0.77
Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations. Clin Transplant (2014) 0.77
Support with the BVS 5000 assist device during treatment of acute giant-cell myocarditis. Tex Heart Inst J (2003) 0.77
Peri-operative renal function and outcome after orthotopic heart transplantation. J Heart Lung Transplant (2006) 0.77
Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Clin Transplant (2007) 0.77
Clinical and angiographic outcomes with everolimus eluting stents for the treatment of cardiac allograft vasculopathy. J Interv Cardiol (2013) 0.76
Taking the rap: multiple effects of blocking mammalian target of rapamycin. Hepatology (2013) 0.75
Microaxial Flow Left Ventricular Assist Device as a Bridge to Transplantation after LVAD Malfunction. Tex Heart Inst J (2015) 0.75
Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support. ASAIO J (2015) 0.75
Frequency of coronary artery fistulae is increased after orthotopic heart transplantation. J Heart Lung Transplant (2013) 0.75
Current concepts for sensitized patients before transplantation. Curr Opin Organ Transplant (2017) 0.75